HUE051734T2 - Piridon-vegyület, mint C-Met inhibitor - Google Patents

Piridon-vegyület, mint C-Met inhibitor

Info

Publication number
HUE051734T2
HUE051734T2 HUE17864813A HUE17864813A HUE051734T2 HU E051734 T2 HUE051734 T2 HU E051734T2 HU E17864813 A HUE17864813 A HU E17864813A HU E17864813 A HUE17864813 A HU E17864813A HU E051734 T2 HUE051734 T2 HU E051734T2
Authority
HU
Hungary
Prior art keywords
met inhibitor
pyridone compound
pyridone
compound
inhibitor
Prior art date
Application number
HUE17864813A
Other languages
English (en)
Inventor
Xiongbin Xu
Gang Li
Charles Z Ding
Lihong Hu
Guoping Hu
Jian Li
Shuhui Chen
Zhigang Chi
Kun Wang
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62024383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE051734(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Publication of HUE051734T2 publication Critical patent/HUE051734T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
HUE17864813A 2016-10-27 2017-10-27 Piridon-vegyület, mint C-Met inhibitor HUE051734T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610954377 2016-10-27

Publications (1)

Publication Number Publication Date
HUE051734T2 true HUE051734T2 (hu) 2021-03-29

Family

ID=62024383

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17864813A HUE051734T2 (hu) 2016-10-27 2017-10-27 Piridon-vegyület, mint C-Met inhibitor

Country Status (28)

Country Link
US (1) US10501443B2 (hu)
EP (1) EP3533787B1 (hu)
JP (1) JP6719679B2 (hu)
KR (1) KR102070748B1 (hu)
CN (1) CN109311812B (hu)
AU (1) AU2017348810B2 (hu)
BR (1) BR112019008415B1 (hu)
CA (1) CA3041164C (hu)
CO (1) CO2019005165A2 (hu)
DK (1) DK3533787T3 (hu)
EA (1) EA038108B1 (hu)
ES (1) ES2835301T3 (hu)
HR (1) HRP20201985T1 (hu)
HU (1) HUE051734T2 (hu)
IL (1) IL266126B (hu)
LT (1) LT3533787T (hu)
MX (1) MX2019004626A (hu)
MY (1) MY189557A (hu)
PE (1) PE20190912A1 (hu)
PH (1) PH12019500875A1 (hu)
PL (1) PL3533787T3 (hu)
PT (1) PT3533787T (hu)
RS (1) RS61126B1 (hu)
SG (1) SG11201903801YA (hu)
SI (1) SI3533787T1 (hu)
UA (1) UA122737C2 (hu)
WO (1) WO2018077227A1 (hu)
ZA (1) ZA201903074B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI768205B (zh) 2018-04-26 2022-06-21 大陸商福建廣生堂藥業股份有限公司 一種c-MET抑制劑的晶型及其鹽型和製備方法
CN113365997B (zh) * 2019-02-01 2022-06-07 南京明德新药研发有限公司 作为c-Met抑制剂的含嘧啶基团的三并环类化合物
WO2022063869A2 (en) 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
EP4346829A1 (en) 2021-06-04 2024-04-10 Merck Patent GmbH Compounds for the treatment of glioblastoma
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275857A1 (en) 2000-06-29 2002-01-14 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
EP1741703A4 (en) 2004-03-05 2009-11-25 Banyu Pharma Co Ltd PYRIDONE DERIVATIVE
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
EP2768826A1 (de) 2011-10-17 2014-08-27 Bayer Intellectual Property GmbH Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer
EP2827872A1 (en) * 2012-03-19 2015-01-28 Merck Patent GmbH Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
WO2014056566A1 (en) * 2012-10-11 2014-04-17 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a mek inhibitor
KR20170090498A (ko) * 2014-12-11 2017-08-07 메르크 파텐트 게엠베하 항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 퀴나졸린 유도체의 조합

Also Published As

Publication number Publication date
JP2019535806A (ja) 2019-12-12
CA3041164A1 (en) 2018-05-03
EP3533787A1 (en) 2019-09-04
DK3533787T3 (da) 2020-11-30
NZ753020A (en) 2021-08-27
CO2019005165A2 (es) 2019-05-31
US20190248763A1 (en) 2019-08-15
BR112019008415A2 (pt) 2019-07-09
ES2835301T3 (es) 2021-06-22
PT3533787T (pt) 2020-11-20
PH12019500875A1 (en) 2019-06-17
CA3041164C (en) 2019-12-17
RS61126B1 (sr) 2020-12-31
SG11201903801YA (en) 2019-05-30
PL3533787T3 (pl) 2021-03-08
KR20190058678A (ko) 2019-05-29
EP3533787B1 (en) 2020-09-30
EA201990952A1 (ru) 2019-11-29
WO2018077227A1 (zh) 2018-05-03
EP3533787A4 (en) 2019-11-13
AU2017348810B2 (en) 2020-05-07
IL266126A (en) 2019-06-30
EA038108B1 (ru) 2021-07-07
LT3533787T (lt) 2020-11-25
AU2017348810A1 (en) 2019-05-23
PE20190912A1 (es) 2019-06-26
CN109311812B (zh) 2020-03-17
UA122737C2 (uk) 2020-12-28
ZA201903074B (en) 2020-01-29
IL266126B (en) 2020-07-30
JP6719679B2 (ja) 2020-07-08
KR102070748B1 (ko) 2020-01-29
US10501443B2 (en) 2019-12-10
CN109311812A (zh) 2019-02-05
BR112019008415B1 (pt) 2020-09-29
MY189557A (en) 2022-02-16
SI3533787T1 (sl) 2021-01-29
MX2019004626A (es) 2019-11-08
HRP20201985T1 (hr) 2021-02-05

Similar Documents

Publication Publication Date Title
ZA201902232B (en) Pyridine compound
IL266745B (en) Benzodiazolonium compounds as enac inhibitors
ZA201903074B (en) Pyridone compound as c-met inhibitor
HK1255832A1 (zh) 吡喃並二吡啶化合物
ZA201900371B (en) Chelate compounds
HK1256022A1 (zh) 唑類取代的吡啶化合物
GB201521524D0 (en) Compound
GB201617103D0 (en) Compound
GB201612652D0 (en) Novel compound
GB201610497D0 (en) Compound
GB201518950D0 (en) Compound
HK1251574A1 (zh) 四氫噁庚英吡啶化合物
GB201619526D0 (en) Compound
GB201619531D0 (en) Compound
GB201613035D0 (en) Compound
GB201608591D0 (en) Compound
GB201520393D0 (en) Compound
GB201520391D0 (en) Compound
GB201509303D0 (en) Compound